Whittington Health Trust has merged is multidisciplinary lung cancer team with its counterpart at neighbouring University College London Hospitals Foundation Trust.

The team will consist of consultant specialists from both trusts who will have an “honorary” contract with both UCLH and Whittington. 

Islington Clinical Commissioning Group’s May board paper confirmed that patients will continue to be treated at both trusts.

It said: “[CCG governing body member] Karen Sennett highlighted the lung cancer multidisciplinary team [at Whittington] for which concerns have been raised; it has been agreed that the lung cancer MDT will be merged with UCLH. Patients will still be treated at Whittington. It is important to monitor these targets during the merge to ensure performance does not slip.”

A spokesman for Whittington said: “We are an established partner of the UCLH Cancer Network. In our commitment to provide the best possible cancer care to our patients locally and to ensure the best decisions on treatment are made, we have agreed to work together with UCLH.

“We believe this is an important step forward in caring for our patients with lung cancer and ensuring that a full range of treatment options are available.”

A spokesman for Islington CCG added: “Islington CCG has no current concerns around the services which Whittington Health delivered to the waiting time standard for 2015-16 and is expected to continue doing so for 2016-17.”